ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 938 • 2019 ACR/ARP Annual Meeting

    TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity

    Alexandre Sepriano1, Sofia Ramiro 2, Stephanie Wichuk 3, Praveena Chiowchanwisawakit 4, Terrie MacCosham 3, Joel Paschke 5, Désirée van der Heijde 1, Robert B.M. Landewé 6 and Walter Maksymowych 7, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3University of Alberta, Edmonton, Canada, 4Mahidol University, Bangkok, Thailand, 5CARE Arthritis, Edmonton, Canada, 6Amsterdam University Medical Center, Amsterdam, Netherlands, 7University of Alberta and CARE Arthritis, Edmonton, Canada

    Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…
  • Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting

    Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis

    DOROTHEE VINSON1, LUC MOLLET-BENHAMOU 2, Yannick Degboe 3, Thao Pham 4, Thomas BARNETCHE 5, Arnaud Constantin 6 and Adeline Ruyssen-Witrand 7, 1AP-HM CHU Marseille, Marseille, France, 2CHU Toulouse, Toulouse, France, 3University of Glasgow, Glasgow, United Kingdom, 4Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, 5CHU Bordeaux, Toulouse, France, 6CHU TOUOUSE, TOULOUSE, France, 7Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France

    Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…
  • Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting

    Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study

    Maya H. Buch1, Bara Erhayiem2, Graham Fent2, Paul Baxter3, Elizabeth M.A. Hensor4, Adam McDiarmid2, Peter Swoboda5, Ananth Kidambi2, David Ripley2, Pankaj Garg2, Sarah Horton4, Raluca Bianca Dumitru4, Kamran Naraghi4, John Greenwood6, Paul Emery7, Sue Pavitt8 and Sven Plein2, 1Leeds Institute of Rheumatic & Musculosekeltal Medicine, University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, 2Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, 7University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 8Leeds School of Dentistry, University of Leeds, Leeds, United Kingdom

    Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
  • Abstract Number: 63 • 2018 ACR/ARHP Annual Meeting

    TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis

    Emily Wu1, Richard Bell2, Edward Schwarz3 and Homaira Rahimi4, 1Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Orthopedeatrics, University of Rochester, Rochester, NY, 4Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY

    Background/Purpose: Interstitial lung disease (ILD) is a significant contributor to rheumatoid arthritis (RA) mortality, yet its pathogenesis remains enigmatic. One theory posits that initial inflammatory…
  • Abstract Number: 2429 • 2018 ACR/ARHP Annual Meeting

    Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study

    Laura Andreoli1, Maria Chiara Gerardi2, Chiara Bazzani3, Matteo Filippini3, Micaela Fredi2, Roberto Gorla3, Maria Grazia Lazzaroni2, Cecilia Nalli2, Marco Taglietti3, Andrea Lojacono4, Sonia Zatti4, Mario Motta5 and Angela Tincani2, 1Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, 4Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, 5Neonatology and NICU, Spedali Civili of Brescia, Brescia, Italy

    Background/Purpose: Treatment with tumor necrosis factors inhibitors (TNFi) during pregnancy may be required to control maternal disease which can be a threat for maternal-fetal well-being.…
  • Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting

    Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?

    Yuki Ishikawa1, Motomu Hashimoto2, Hiromu Ito3, Masao Tanaka2, Naoichiro Yukawa4, Takao Fujii5, Wataru Yamamoto6, Tsuneyo Mimori7 and Chikashi Terao8,9,10, 1One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, 5Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, 6Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, 7Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 8Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, 9Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, 10Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

    Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
  • Abstract Number: 2557 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis

    Philip Helliwell1, Dafna D Gladman2, Soumya D Chakravarty3, Shelly Kafka4, Chetan S Karyekar4, Yin You5, Arthur Kavanaugh6 and Lianne S. Gensler7, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK, Leeds, United Kingdom, 2Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Janssen Research & Development, LLC, Spring House, PA, 6University of California, San Diego, School of Medicine, La Jolla, CA, 7University of California San Francisco, San Francisco, CA

    Background/Purpose: In PSUMMIT 1&2, Phase 3 trials of ustekinumab (UST) in adults w/ active psoriatic arthritis (PsA), 30.1% & 22.4% of patients (pts) had peripheral…
  • Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting

    The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study

    Axel Finckh1, Christophe Tellenbach2, Almut Scherer2, Burkhard Moeller3, Adrian Ciurea4, Ines von Mühlenen5, Cem Gabay6, Diego Kyburz7, Ruediger Mueller8, Paul Hasler9 and Pascal Zufferey10, 1University Hospital of Geneva, Geneva, Switzerland, 2SCQM Foundation, Zurich, Switzerland, 3Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, 4Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Rheuma-Basel, Basel, Switzerland, 6University Hospitals of Geneva, Geneva, Switzerland, 7Rheumatology, University Hospital Basel, Basel, Switzerland, 8Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, 9Kantonsspital Aarau AG, Aarau, Switzerland, 10Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland

    Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
  • Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)

    Robert B.M. Landewé1, Désirée van der Heijde2, Maxime Dougados3, Xenofon Baraliakos4, Filip van Den Bosch5, Bengt Hoepken6, Karen Thomas6 and Lianne S. Gensler7, 1Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, 4Ruhr-University Bochum, Herne, Germany, 5Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, 6UCB Pharma, Monheim, Germany, 7University of California, San Francisco, CA

    Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…
  • Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting

    Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis

    Josef S. Smolen1, Young Mo Kang2, Wan-Hee Yoo3, Paul Emery4, Michael E Weinblatt5, Edward C. Keystone6, Mark C. Genovese7, Gihyun Myung8, Evelyn Hong8, Inyoung Baek8 and Jeehoon Ghil8, 1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 2Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), 3Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), 4University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 5Brigham and Women's Hospital, Boston, MA, 6Mount Sinai Hospital, Toronto, ON, Canada, 7Stanford University Medical Center, Palo Alto, CA, 8Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)

    Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
  • Abstract Number: 2580 • 2018 ACR/ARHP Annual Meeting

    Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison

    Theresa Hunter1, Atul A. Deodhar2, Rebecca Bolce1, Krista Schroeder1 and David Sandoval Calderon1, 1Eli Lilly and Company, Indianapolis, IN, 2Oregon Health & Science U, Portland, OR

    Background/Purpose: The purpose of this study was to compare treatment patterns in the 2 years following the initiation of TNF inhibitor (TNFi) in AS patients.Methods:…
  • Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting

    Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

    Borja Hernández-Breijo1,2, Israel Gañán-Nieto3, Cristina Sobrino3, Victoria Navarro-Compán1, Ana Martínez1,2, Carlota García-Hoz3, Javier Bachiller3, María Gema Bonilla Hernán1,4, Garbiñe Roy5, Mónica Vázquez3, Alejandro Balsa1,6, Luisa María Villar3, Dora Pascual-Salcedo1, Eulalia Rodríguez-Martín3 and Chamaida Plasencia1,4, 1Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, 2Immunology. La Paz University Hospital, Madrid, Spain, 3Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, 4Rheumatology, La Paz University Hospital, Madrid, Spain, 5Immunology. Ramón y Cajal University Hospital and IRYCIS, Madrid, Spain, 6Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…
  • Abstract Number: 2599 • 2018 ACR/ARHP Annual Meeting

    The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study

    Tanja Schjødt Jørgensen1, Marie Skougaard1, Rebekka L Hansen1, Christine Ballegaard1, Philip J. Mease2, Vibeke Strand3, Lene Dreyer4 and Lars Erik Kristensen1, 1The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, 2Swedish Medical Center and University of Washington, Seattle, WA, 3Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 4Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University., Hellerup, Denmark

    Background/Purpose:  Despite better control of inflammation, e.g. with biological treatments, some patients with psoriatic arthritic (PsA) continue to cite fatigue as one of the most…
  • Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting

    Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry

    Nancy A. Shadick1, Michael E Weinblatt1, Christine K Iannaccone2, Michelle Frits3, Tigwa Davis4, Christopher Young4, David H. Collier5, Mahdi Gharaibeh5 and Bradley S. Stolshek6, 1Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Health Analytics, LLC, Columbia, MD, 5Amgen Inc., Thousand Oaks, CA, 6Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
  • Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders

    Jeffrey Crowley1, Kim A Papp2, Chih-ho Hong3, Jeff Parno4, Alan M Mendelsohn4, Qing Li5 and Nicole Cichanowitz5, 1Bakersfield Dermatology, Bakersfield, CA, 2Probity Medical Research, Waterloo, ON, Canada, 3University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, 5Merck & Co., Inc., Kenilworth, NJ

    Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology